FindTrial
Sign In

BMF-219

DRUG4 trials

Sponsors

Biomea Fusion Inc.

Conditions

Acute Lymphoblastic LeukemiaAcute Mixed-Phenotype LeukemiaAcute Myeloid LeukemiaCRCCancerChronic Lymphocytic LeukemiaColorectal CancerDiffuse Large B Cell Lymphoma

Phase 1

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
TerminatedNCT05153330
Biomea Fusion Inc.Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Acute Myeloid Leukemia +12
Start: 2022-01-24End: 2025-05-02Updated: 2025-07-03
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
TerminatedNCT05631574
Biomea Fusion Inc.Colorectal Cancer, CRC, KRAS Mutation-Related Tumors +14
Start: 2023-01-12End: 2025-01-15Updated: 2025-02-07
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
CompletedNCT05731544
Biomea Fusion Inc.Type 2 Diabetes Mellitus
Start: 2022-08-17End: 2025-07-08Updated: 2025-11-10

Phase 2

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
CompletedNCT06152042
Biomea Fusion Inc.Type 1 Diabetes Mellitus
Start: 2023-12-28End: 2025-07-18Updated: 2026-08-28

Related Papers

Design, synthesis, and evaluation of Menin-targeting compounds for the treatment of acute Myelocytic leukemia (AML).
2025-06-12
901-P: COVALENT 112—A Clinical Trial Assessing BMF-219, an Oral Covalent Menin Inhibitor in Type 1 Diabetes
Diabetes2024-06-14
Abstract 3314: Molecular profiling of covalent menin inhibitor, BMF-219, in KRAS-mutated solid tumors
Cancer Research2024-03-22
COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in adults with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC) and colorectal cancer (CRC) with activating KRAS mutations.
Journal of Clinical Oncology2024-01-201 citations
Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study
Blood2023-11-0224 citations
91-LB: COVALENT-111, a Phase 1/2 Trial of BMF-219, a Covalent Menin Inhibitor, in Patients with Type 2 Diabetes Mellitus—Preliminary Results
Diabetes2023-06-203 citations
Abstract A003: COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC), and colorectal cancer (CRC) with activating KRAS mutations
Molecular Cancer Research2023-05-01
Abstract 3457: Characterization of acquired resistance mutations to menin inhibitors
Cancer Research2023-04-049 citations
Abstract CT210: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as single-agent in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM)
Cancer Research2022-06-15
COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).
Journal of Clinical Oncology2022-06-0111 citations
P587: COVALENT-101: A PHASE 1 STUDY OF BMF-219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, AND MULTIPLE MYELOMA
HemaSphere2022-06-012 citations